TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02277652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GlideScope Ranger
Description: Videolaryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Supraglottic Airway Laryngopharyngeal Tube (SALT)
Description: Blind intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Supraglottic Airway Laryngopharyngeal Tube (SALT)
Description: Blind intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Supraglottic Airway Laryngopharyngeal Tube (SALT)
Description: Blind intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Supraglottic Airway Laryngopharyngeal Tube (SALT)
Description: Blind intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Supraglottic Airway Laryngopharyngeal Tube (SALT)
Description: Blind intubation
Study: NCT03055338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
Study: NCT01309633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
Description: Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
Study: NCT02273180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
Study: NCT03055338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching MK-8189
Description: Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching MK-8189
Description: Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching risperidone
Description: Oral placebo capsule(s) matching the risperidone capsule, administered QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching risperidone
Description: Oral placebo capsule(s) matching the risperidone capsule, administered QD.
Study: NCT04192071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual technology - high interactive
Description: Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer and dietary intake. Interactive nutrition risk feedback will be customized based on user input.
Study: NCT02277652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Supraglottic Airway Laryngopharyngeal Tube (SALT)
Description: Blind intubation
Study: NCT04192071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual technology - low interactive
Description: Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer. Minimally interactive risk feedback will be delivered.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-colorectal cancer related module
Description: Participants engage with web-based content not related to colorectal cancer or nutrition.
Study: NCT02971956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor
Study: NCT00532389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03285867

Intervention type: PROCEDURE
Intervention: TACE
Description: transcatheter arterial chemoembolization
Study: NCT03297320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-depth conversation about Goals of Care and ACP
Description: In-depth conversation regarding Goals of Care and ACP by an experienced practitioner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-depth conversation about Goals of Care and ACP
Description: In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
Study: NCT01957098

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: 0% pentose
Description: 14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: 4% D-xylose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: 8% D-xylose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: 8% L-arabinose
Study: NCT01130441

Intervention type: BEHAVIORAL
Intervention: psychotherapy
Description: short problem-solving skills therapy intervention
Study: NCT01745536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocytes are vitrified/stored using a closed device
Description: Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oocytes are vitrified/stored using an open device
Description: The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
Study: NCT02868190

Intervention type: DEVICE
Group type: OTHER
Intervention: Two trabecular micro-bypass stents (iStent inject)
Description: Standalone implantation of two trabecular micro-bypass stents (iStent inject)
Study: NCT05051280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography fusion image
Description: Left Atrial Appendage Occlusion Under Cone-beam Computed Tomography Fusion Image Guidance
Study: NCT01152879

Intervention type: DIETARY_SUPPLEMENT
Intervention: Home Parenteral Nutrition
Description: Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
Study: NCT03551171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306 (niraparib)
Description: About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose.
Study: NCT04846283

Intervention type: PROCEDURE
Intervention: Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure
Description: We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
Study: NCT03525938

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: TAP block
Description: Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
Study: NCT03902873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real-time audiovisual feedback
Description: During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
Study: NCT03090958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AllyQuest
Description: AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
Study: NCT02552069

Intervention type: DEVICE
Intervention: Tritanium® cup
Study: NCT02139202

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Influence

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic Pill Bottles

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial Incentives
Study: NCT00619892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine XR
Description: Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
Study: NCT03028909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Standard of care for influenza caused by Type A strains

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Standard of care for influenza caused by Type A strains

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Standard of care for influenza caused by Type A strains

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
Study: NCT01506193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PriorixTetra™
Description: One dose administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTetra™
Description: One dose administered subcutaneously
Study: NCT03028909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Salt-water solution containing no active ingredients.
Study: NCT03527589

Intervention type: DEVICE
Intervention: Prostate artery embolization
Description: Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
Study: NCT01232413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral
Study: NCT02420080

Intervention type: DRUG
Intervention: Brincidofovir
Description: Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.

Intervention type: DRUG
Intervention: Brincidofovir
Description: Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
Study: NCT03558763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: During the telemonitoring treatment period the subjects will register; vital functions (blood pressure, heart rate, weight, SpO2) twice a week, physical movement daily by using a fitness device, have video calls with a nurse weekly the first 4 weeks and thereafter every fourth week the last 5 months. Twice a week (± 2 days) questionnaires (CAT and MRC) should be filled out at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Care
Description: During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
Study: NCT02533245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based indiviualized exercise training program
Description: Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised group training sessions
Description: 7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised group training sessions
Description: 7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climb of the Mont Ventoux
Description: Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climb of the Mont Ventoux
Description: Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
Study: NCT04221256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of SSRI escitalopram
Description: Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Paired Associative stimulation
Description: Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired Associative stimulation
Description: Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of Placebo
Description: Participants will be administered a placebo prior to paired associative stimulation
Study: NCT03515811

Intervention type: DEVICE
Intervention: Signia™ Stapling System
Description: Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.

Intervention type: DEVICE
Intervention: Signia™ Stapling System
Description: Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
Study: NCT04001296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 21 day Brush Day and Night school programme
Description: Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
Study: NCT01259622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201
Description: intravenous infusion
Study: NCT00907491

Intervention type: DEVICE
Intervention: pulmonary sounds analyzer
Description: Cough counting device based on the WIM Technology
Study: NCT03773406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offline tDCS-before therapy
Description: Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
Study: NCT02732561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Stim device
Description: cranial electrotherapy stimulation device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham device
Study: NCT03773406

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Stimulation will be given for a total 30 seconds (including ramp-up and ramp-down of current) and then the tDCS device will be turned off. The brief stimulation will produce tDCS-induced sensation so that participants will not be aware when the tDCS was turned off .We will use standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offline tDCS-after therapy
Description: Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online tDCS
Description: Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
Study: NCT01506193

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: One dose administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: One dose administered intramuscularly
Study: NCT00685919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: 200 mg every 6 hours for 5 doses given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: 200 mg every 6 hours for 5 doses given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: every 6 hours for 5 doses, given orally, and matching Carbidopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: every 6 hours for 5 doses, given orally, and matching Carbidopa
Study: NCT02742090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib was administered as a tablet(s), orally once daily.
Study: NCT01506193

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: One dose administered intramuscularly
Study: NCT01689064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stamm Approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Septectomy
Study: NCT01272557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400 mg bid (oral) continuously
Study: NCT02964728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin Type A
Description: topical injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: topical injection
Study: NCT02444533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
Study: NCT02161952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched equivalent placebo